We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the first patient treated under an Investigational Device Exemption, aiming to secure FDA Premarket Approval for its GalaFLEX LITE Scaffold. The trial focuses on evaluating the scaffold's ability to reduce the recurrence of capsular contracture (“CC”) in breast revision surgeries.
By advancing this innovative solution, BD is working to address unmet needs in breast reconstruction procedures. The trial reflects the company’s commitment to developing advanced surgical materials that can improve patient recovery, safety and satisfaction.
Likely Trend of the BDX Stock Following the News
Following the announcement, shares of the company closed flat at $230.23 on Friday. In the past six months, BDX’s shares have lost 2.8% compared with the industry’s 2.8% growth. The S&P 500 lost 0.8% in the same time frame.
However, this news could boost the BDX stock in the long run as this shows the company is innovating in a growing surgical market. If the GalaFLEX LITE scaffold proves successful, it can lead to higher demand from surgeons and hospitals seeking better patient outcomes in breast surgeries. This could open up a new revenue stream, strengthen BD’s position in advanced surgical materials and improve profitability over time, all of which can positively influence investor confidence and the stock price.
Meanwhile, BDX currently has a market capitalization of $66.11 billion. The company delivered an earnings surprise of 15.1% in the last reported quarter.
Image Source: Zacks Investment Research
Details on BDX’s STANCE Study
Implant-based breast surgeries are among the most common plastic surgeries in the United States, with CC being the leading complication, affecting 10% to 20% of patients. CC occurs when scar tissue around the implant hardens, causing pain and implant displacement, often requiring revision surgery with a high risk of recurrence.
BD’s pivotal STANCE study evaluates whether the bioabsorbable GalaFLEX LITE Scaffold can reduce CC recurrence and implant malposition compared with standard revision surgery without a supportive matrix. The randomized, multi-center trial will enroll at least 250 patients across 40 sites, with a 2:1 ratio of patients receiving the scaffold versus standard care, aiming to demonstrate its safety and effectiveness in improving surgical outcomes.
More on BD’s GalaFLEX LITE Scaffold
GalaFLEX LITE Scaffold is an advanced, bioabsorbable surgical mesh, which is designed to provide temporary support to soft tissue during the healing process. Made from P4HB, a naturally derived polymer, the scaffold gradually dissolves in the body over time, leaving behind strengthened, regenerated tissue. It is specifically engineered to be lightweight yet strong, offering the necessary reinforcement without adding long-term foreign material.
In breast implant revision surgeries, the GalaFLEX LITE Scaffold is used to help prevent complications like CC and implant malposition by supporting tissue integration and reducing mechanical stress. Its bioabsorbable nature minimizes long-term risks and eliminates the need for additional procedures to remove the scaffold, making the mesh an innovative solution in the field of reconstructive and aesthetic surgery.
Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the first patient treated under an Investigational Device Exemption, aiming to secure FDA Premarket Approval for its GalaFLEX LITE Scaffold. The trial focuses on evaluating the scaffold's ability to reduce the recurrence of capsular contracture (“CC”) in breast revision surgeries.
By advancing this innovative solution, BD is working to address unmet needs in breast reconstruction procedures. The trial reflects the company’s commitment to developing advanced surgical materials that can improve patient recovery, safety and satisfaction.
Likely Trend of the BDX Stock Following the News
Following the announcement, shares of the company closed flat at $230.23 on Friday. In the past six months, BDX’s shares have lost 2.8% compared with the industry’s 2.8% growth. The S&P 500 lost 0.8% in the same time frame.
However, this news could boost the BDX stock in the long run as this shows the company is innovating in a growing surgical market. If the GalaFLEX LITE scaffold proves successful, it can lead to higher demand from surgeons and hospitals seeking better patient outcomes in breast surgeries. This could open up a new revenue stream, strengthen BD’s position in advanced surgical materials and improve profitability over time, all of which can positively influence investor confidence and the stock price.
Meanwhile, BDX currently has a market capitalization of $66.11 billion. The company delivered an earnings surprise of 15.1% in the last reported quarter.
Image Source: Zacks Investment Research
Details on BDX’s STANCE Study
Implant-based breast surgeries are among the most common plastic surgeries in the United States, with CC being the leading complication, affecting 10% to 20% of patients. CC occurs when scar tissue around the implant hardens, causing pain and implant displacement, often requiring revision surgery with a high risk of recurrence.
BD’s pivotal STANCE study evaluates whether the bioabsorbable GalaFLEX LITE Scaffold can reduce CC recurrence and implant malposition compared with standard revision surgery without a supportive matrix. The randomized, multi-center trial will enroll at least 250 patients across 40 sites, with a 2:1 ratio of patients receiving the scaffold versus standard care, aiming to demonstrate its safety and effectiveness in improving surgical outcomes.
More on BD’s GalaFLEX LITE Scaffold
GalaFLEX LITE Scaffold is an advanced, bioabsorbable surgical mesh, which is designed to provide temporary support to soft tissue during the healing process. Made from P4HB, a naturally derived polymer, the scaffold gradually dissolves in the body over time, leaving behind strengthened, regenerated tissue. It is specifically engineered to be lightweight yet strong, offering the necessary reinforcement without adding long-term foreign material.
In breast implant revision surgeries, the GalaFLEX LITE Scaffold is used to help prevent complications like CC and implant malposition by supporting tissue integration and reducing mechanical stress. Its bioabsorbable nature minimizes long-term risks and eliminates the need for additional procedures to remove the scaffold, making the mesh an innovative solution in the field of reconstructive and aesthetic surgery.
BDX’s Zacks Rank & Stocks to Consider
BDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carries a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.